MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals.
We have the world’s highest quality antibody libraries (MOURA Libraries) in terms of functionality and completeness, as well as highly efficient monoclonal antibody isolation technology (IMPACT). By using these, we make it possible to obtain quality monoclonal antibodies that recognize unique 3D structures or subtle structural differences of target molecules such as membrane proteins, thus contributing to new drug development opportunities in the pharmaceutical industry.
MabGenesis is focused on human and animal antibody pharmaceutical business.
In human pharmaceutical area, MabGenesis is committed to obtain innovative therapeutic antibodies to meet unmet medical needs, especially, cancer and zoonotic diseases.
In animal pharmaceutical area which is rapidly growing, MabGenesis has already established canine and feline MOURA antibody libraries that allow for the discovery of high-quality antibodies for the treatment of various diseases. Our goal is to be a global innovator in animal antibody therapeutics.
An antibody drug is a drug that utilizes an antibody that exists in a living body. By selectively binding to target molecules (antigens), antibody drugs perform various pharmacological effects.
The antibody drug market is expected to exceed 14 trillion yen in 2020, and “fully human antibodies”, which are expected to have higher efficacy and safety in the future, have become the mainstream of antibody drugs.
In the future, with the aging of companion animals (dogs and cats), it is expected that the market for complete dog/cat antibodies, which are more effective and safer for pets, will increase.
